Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834

Q1 FY27 results · Apr–Jun 2026

Camlin Fine Sciences reported revenue from operations of ₹519.88 crore (up 22.7% from Q1 FY26) and net loss of ₹33.62 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	519.88	423.55	+22.7%	424.81	+22.4%
Other income	1.34	8.56	−84.4%	23.91	−94.4%
Total income	521.22	432.12	+20.6%	448.72	+16.2%
Profit before share of associates & JVs and tax	(33.66)	(5.15)	Loss widened	(6.65)	Loss widened
Share of profit/(loss) of associates & JVs	1.40	0.89		1.38
Net profit for the period	(33.62)	(10.68)	Loss widened	86.28	Turned loss
Attributable to shareholders of the company	(31.71)	(9.96)	Loss widened	88.20	Turned loss
EPS, basic (₹)	(1.65)	(0.53)	Loss widened	4.59	Turned loss
Net margin (%)	-6.5	-2.5		20.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	222.49	191.44	+16.2%	183.52	+21.2%
Other income	1.40	3.69	−62.0%	15.30	−90.8%
Total income	223.89	195.13	+14.7%	198.82	+12.6%
Profit before tax	(18.67)	(16.38)	Loss widened	(16.64)	Loss widened
Net profit for the period	(12.31)	(10.68)	Loss widened	(5.65)	Loss widened
EPS, basic (₹)	(0.64)	(0.57)	Loss widened	(0.29)	Loss widened
Net margin (%)	-5.5	-5.6		-3.1

Consolidated

Filed with BSE: 11 Aug 2026, 18:26 IST
Board meeting: 11 Aug 2026
Period: 01 Apr 2026 to 30 Jun 2026
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 11 Aug 2026, 18:26 IST
Board meeting: 11 Aug 2026
Period: 01 Apr 2026 to 30 Jun 2026
Review status: Unaudited
Source: XBRL filing on BSE